Subscribe Become an Author Sign Up Log In

e-therapeutics

Company
Founded
2003
Status
Private
Geography
United Kingdom based
Funding
$2.865 M
Patents
8
Research papers
3

About

We are an Oxford, UK-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.

Our novel network-driven methodology allows us to discover new and better drugs in a more efficient and effective way.

We use our highly productive drug Discovery Engine to develop our own IP-protected, preclinical drug discovery programmes which will be of interest to partners looking to acquire or in-license novel and differentiated assets.

Because of our novel network-driven drug (NDD) discovery approach, we believe there is potential to enter into several different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.

Business model
  • Drug Candidate as a Service (DCaaS)
Therapeutic focus
  • Immunology
  • Oncology
Research focus
  • Data mining / Ontology building
  • Lead Discovery

Investing history

2009Unknown Round2.865

Industry Partnerships

YearPartnerFocus
2018Novo NordiskIdentify novel intervention strategies, biological pathways and compounds that could form the basis of new therapies.

Posts Mentioning This Company

Biopharma Insights
Video gallery